Sjögren's disease & overlap diseases
Impact of patient ancestry on heterogeneity of Sjögren’s disease
Authors' conclusion
Patients of AA display higher disease activity with a hallmark of higher B-cell activation.
Study context
- Population
- Primary Sjögren's syndrome (pSS) patients at a French national and European referral centre for pSSmedian follow-up 6 years
- Participants
- 74 vs 148
- Comparison
- pSS patients of African ancestry vs Caucasian ancestry
- African ancestry (AA)n = 74
- Caucasiann = 148reference
- Outcome
- Disease activity: cumESSDAI ≥5 (individual clinESSDAI domain maximum throughout follow-up)
Methodological detailsmatched on follow-up duration (two Caucasian per African ancestry patient), national and European referral centre, multivariate analysis
- Matched on follow-up duration (two Caucasian per African ancestry patient)
- National and European referral centre
- Multivariate analysis
Main finding
As reported in the abstract
Median cumESSDAI score
AA
7.5
median · IQR 3.2–16.0
Caucasian
4.0
median · IQR 2.0–9.0
P = 0.002
Observational data: associations, not effects.
Further findings
Factors associated with disease activity (cumESSDAI ≥5), multivariate
| OR (95% CI) | ||
|---|---|---|
| Sub-Saharan AA | 2.65 (1.06–6.94) | |
| Rheumatoid factor | 2.50 (1.28–4.96) | |
| Anti-RNP positivity | 11.1 (1.88–212) | |
| 0.050.21520Odds ratio (log scale) |
Median age at pSS diagnosis
P < 0.001
Median gammaglobulin titre
P < 0.001
Anti-SSA positivity
P = 0.007
Anti-RNP positivity
P = 0.023
Systemic complications during follow-up · median 6 years (IQR 2-11)
- AA patients presented more systemic complications: arthritis, myositis, ILD, lymphadenopathy, CNS involvement
Original publication
Impact of patient ancestry on heterogeneity of Sjögren’s disease. RMD Open. Published 6 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →